An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Rintatolimod (Primary)
- Indications Chronic fatigue syndrome; Encephalomyelitis
- Focus Adverse reactions; Expanded access; Registrational
- Sponsors Hemispherx Biopharma
- 28 Jun 2018 Status changed from active, no longer recruiting to recruiting.
- 27 Jun 2018 According to a Hemispherx Biopharma media release, this trial will enrol new patients at Hunter-Hopkins Center, North Carolina and Sierra Internal Medicine in Nevada.
- 21 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.